Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,758 total articles
Adobe's AI initiatives have produced real revenue momentum (AI-first ARR > $500M) and the business still throws off outstanding cash, but the stock has retraced sharply and faces near-term execution and monetization risks. For disciplined traders, a measured mid-term long on a pullback offers asymmetric reward versus risk: entry near $248, stop at …
RMR Group yields ~9% at current prices but, crucially, free cash flow now covers the dividend with room to spare. The company is trading at attractive FCF and EV multiples, and the next 45 trading days present a favorable window for a risk-managed long. Key risks include dividend volatility tied to client performance and macro pressures on REITs.
Phillips 66 (PSX) has outperformed as refining crack spreads surge and the company converts windfall margins into cash flow and strategic investments. I was wrong about how long the margin cycle would last, but not about the underlying cyclical thesis. This article lays out a mid-term trade: buy a disciplined pullback to $255 with a $295 target and…
Iridium trades at $47.20, well below the implied $75/sh takeout price implied by headlines about Rocket Lab's $8B acquisition. The gap is large enough to justify a neutral/hold position as a merger-arb, but the trade is conditional on deal structure, financing path, and regulatory progress. Use a defined entry, stop and target and treat this as a l…
Opus Genetics announced a clear clinical success that meaningfully de-risks its lead program and creates several commercialization pathways. The stock has room to re-rate as the company transitions from binary trial risk to execution and partnership optionality. We recommend a long position with defined entry, stop and target levels and a 180 tradi…
Northern Oil and Gas (NOG) looks like a reasonable long from current levels as Q2 unit economics and oil price support strengthen free-cash-flow prospects. Market cap is $2.77B with EV/EBITDA ~3.1, a near-7% yield and a hefty analyst target range — this trade captures an asymmetric risk/reward over 180 trading days with a strict stop.
Tourmaline (TRMLF) is a cash-generative Western Canadian producer trading at a $17.5B market cap with a 3.2% yield. Improving capital efficiency and early-stage AI deployment in upstream operations could unlock a multi-quarter re-rating. This trade targets a measured long with a favorable risk/reward and a 180 trading-day horizon.
Aptiv (APTV) trades near 52-week lows after program delays and China weakness. The stock's $9.38B market cap, modest EV/EBITDA of 5.1, and $763M in free cash flow give it a valuation floor while global ADAS, vehicle control units, and cable assembly markets expand. This idea sizes Aptiv as a small, tactical long for investors willing to tolerate ex…
CoreWeave's gargantuan revenue backlog and sustained top-line acceleration argue for a buy-the-dip approach. The business is capital-intensive and highly leveraged, but the order book gives revenue visibility that can absorb near-term interest pain. This trade idea outlines entry, stop, targets, catalysts and what would change the thesis.
Royal Caribbean (RCL) has retraced sharply despite beating recent earnings and raising FY2026 EPS guidance. Elevated fuel, payroll pressures and geopolitical risks justify caution, yet valuation, record pricing and an oversold technical set-up create a favorable asymmetric trade. This idea lays out an entry at $255.00, stop at $235.00 and a target …
Sony is trading at a reasonable market cap of ~$142.4B while sitting on diversified, improving revenue engines. Recent technicals show consolidation after a summer pullback; fundamentals and strategic catalysts (digital gaming shift, generative AI in music, robotics partnerships) support upside toward prior highs. This trade idea offers a defined e…
Darling Ingredients (DAR) is showing sustained operational recovery across Feed, Food and Fuel Ingredients with healthy free cash flow and reasonable leverage. Technical momentum and a manageable valuation create a favorable risk/reward for a mid-term swing trade. Entry at $67.00, target $74.00, stop loss $61.00; time horizon: mid term (45 trading …
Alphabet is spending at a scale that materially depresses free cash flow today, but earnings and core franchise metrics leave the stock reasonably valued on a P/E basis. This trade targets a mean-reversion in sentiment and a normalization of capex intensity across the next 6 months. Entry $328.00, stop $305.00, target $380.00 - long for 180 trading…
Shares of Marvell (MRVL) have sold off on headlines about a large hyperscaler decision, but the pullback looks disproportionate to the company's fundamentals. With a $204B market cap, robust free cash flow, healthy margins and continued hyperscaler capex, this is a measured mid-term long trade: enter $233.00, target $270.00, stop $215.00. The thesi…
CMB.TECH remains our favored way to play structural modernization in shipping. Fundamentals around fleet-digitization, recurring software revenue and improving gross margins keep the bull case intact. This update lays out an actionable long trade with defined entry at $8.50, a protective stop at $6.25 and an initial target of $14.00 over the next 1…
SharpLink (SLNK) is trading at roughly 0.85x MNAV and carries no debt. For investors who want direct crypto cycle exposure without leverage on the balance sheet, this looks like a compelling asymmetric trade. Entry $34.00, target $48.00, stop $28.00; mid-to-long-term horizon with catalysts around ETH price recovery and improved operating optionalit…
Apple’s 09/10/2026 product announcements (iPhone Ultra and AI-enhanced Siri) materially change the revenue leverage case for its services and device ecosystem. With $4.65T market cap, $136.7B free cash flow and a still-premium 36x P/E, Apple is priced for growth but not perfection. We lay out a long trade (entry $318.77, target $360.00, stop $295.0…
Bio-Rad is trading below recent highs after an investor-event bump tied to Elliott's stake. The company carries valuable optionality from its Sartorius holding, generates meaningful free cash flow, and sits at a valuation that could re-rate if management takes decisive action. We lay out a tactical long with entry, stop, and target for a 45-trading…
Formula 1’s calendar expansion and rising sponsorship/media monetization are underappreciated drivers for Liberty’s FWONK shares. The shares trade below many of their moving averages after a summer drift; the business generates meaningful free cash flow ($802M) and sits on an enterprise value of roughly $27.7B. This trade aims to capture the compou…
Oportun (OPRT) looks cheap and is finally executing. Improved funding costs, a $485M ABS at sub-6% yields, meaningful corporate debt paydowns and growing adoption of AI-powered savings features create a near-term catalyst runway. We upgrade to Buy with a defined entry, stop and target for a 45-trading-day swing trade.
United Natural Foods (UNFI) has cut its top-line outlook but improved profitability and free cash flow. Market cap near $2.7B and an EV/EBITDA of ~8x price a company showing margin leverage; this trade seeks to capture further margin-driven re-rating while limiting downside with a clear stop.
Pfizer's combination of strong free cash flow, a 6.1% yield, recent regulatory wins and an upgraded revenue outlook make the stock a pragmatic swing trade. We'll lay out an entry, target and stop with a mid-term horizon and the risks that could derail the setup.
Nano Labs is a micro-cap semiconductor and AI-infrastructure hopeful pivoting from crypto exposure toward AI and Web3. The stock trades at $2.29, technical momentum is constructive and insider/partnership signals provide catalysts, but recent cash losses, tiny revenues, and outsized short interest make position sizing and entry critical. This trade…
Waystar's specialty in healthcare payments is starting to show through accelerating subscription adoption and robust cash generation. With a market cap near $4.6B, a clean balance sheet and recent AI-enabled product wins, the risk/reward favors a mid-term buy. Trade plan includes an entry at $23.95, target $32.00 and stop $20.50 for a 45-trading-da…
Marubeni trades at $32.62 with a $54.2B market cap, a P/E of 14.8 and PB of 2.0. Recent purchases by Berkshire Hathaway, steady dividend yield (1.82%) and bullish technicals set the stage for a mid-term rerating. Enter at $32.50, target $38.00, stop $29.00 — horizon: mid term (45 trading days).
